Optipharm.CO.LTD Balance Sheet Health
Financial Health criteria checks 5/6
Optipharm.CO.LTD has a total shareholder equity of ₩25.1B and total debt of ₩9.6B, which brings its debt-to-equity ratio to 38.2%. Its total assets and total liabilities are ₩39.3B and ₩14.1B respectively.
Key information
38.2%
Debt to equity ratio
₩9.61b
Debt
Interest coverage ratio | n/a |
Cash | ₩15.65b |
Equity | ₩25.14b |
Total liabilities | ₩14.13b |
Total assets | ₩39.28b |
Recent financial health updates
Health Check: How Prudently Does Optipharm.CO.LTD (KOSDAQ:153710) Use Debt?
Mar 30Optipharm.CO.LTD (KOSDAQ:153710) Has Debt But No Earnings; Should You Worry?
Dec 15Recent updates
Health Check: How Prudently Does Optipharm.CO.LTD (KOSDAQ:153710) Use Debt?
Mar 30What Kind Of Shareholders Hold The Majority In Optipharm.CO.,LTD's (KOSDAQ:153710) Shares?
Feb 23Should Optipharm.CO.LTD (KOSDAQ:153710) Be Disappointed With Their 52% Profit?
Jan 19Optipharm.CO.LTD (KOSDAQ:153710) Has Debt But No Earnings; Should You Worry?
Dec 15Financial Position Analysis
Short Term Liabilities: A153710's short term assets (₩20.5B) exceed its short term liabilities (₩11.6B).
Long Term Liabilities: A153710's short term assets (₩20.5B) exceed its long term liabilities (₩2.5B).
Debt to Equity History and Analysis
Debt Level: A153710 has more cash than its total debt.
Reducing Debt: A153710's debt to equity ratio has increased from 12.4% to 38.2% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A153710 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: A153710 has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 44.8% each year